移植物抗宿主病发病机制研究进展
本文综述了急性移植物抗宿主病(GVHD)发病机制的最新进展,聚焦疾病早期事件,包括组织损伤因子、固有免疫细胞、共刺激通路、免疫细胞信号传导、免疫调节细胞类型、GVHD生物标志物及再生策略。新见解揭示了促炎细胞内信号传导、肠道组织再生与抗菌防御缺陷以及微生物组多样性降低的作用,这些将作为开发新疗法的基础。
要点
- 移植后环磷酰胺或抗胸腺细胞球蛋白等免疫预防策略降低了急性GVHD发生率。
- 新型免疫刺激药物(如免疫检查点抑制剂、来那度胺)可能改变临床所见的急性GVHD生物学特征。
- 促炎信号、肠道再生与抗菌防御缺陷及微生物组多样性降低是新型疗法的开发基础。
核心结论
- 对急性GVHD发病机制的新认识揭示了促炎细胞内信号、肠道组织再生与抗菌防御缺陷及微生物组多样性降低的作用,为开发新疗法提供了基础。
研究设计与样本
- 本文为综述,聚焦急性GVHD早期事件,包括组织损伤因子、固有免疫细胞、共刺激通路、免疫细胞信号传导、免疫调节细胞类型、生物标志物及再生策略。
主要发现
- 移植后环磷酰胺或抗胸腺细胞球蛋白等免疫预防策略近年降低了急性GVHD发生率。
- 免疫检查点抑制剂或来那度胺等新型免疫刺激药物在allo-HSCT前后使用可能改变临床所见的急性GVHD生物学特征。
- 新见解揭示了促炎细胞内信号传导、肠道组织再生与抗菌防御缺陷以及微生物组多样性降低的作用。
临床怎么用
- 关注免疫预防策略对急性GVHD发生率的影响,并警惕新型免疫刺激药物可能改变GVHD生物学特征。
- 基于早期事件(如促炎信号、肠道再生与抗菌防御、微生物组)探索新型疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft-versus-host disease (GVHD) remains a major complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT). The emergence of different immuno-prophylaxis strategies, such as post-transplant cyclophosphamide or anti-thymocyteglobulin has reduced the incidence of acute GVHD in recent years. The biology of the acute GVHD we observe in the clinic may change due to the use of novel immuno-stimulatory agents, including immune checkpoint inhibitors or anti-neoplastic immune-modifiers, like lenalidomide, given before or after allo-HSCT. Here we discuss the recent advances in our understanding of acute GVHD with a focus on early events of the disease, including tissue damaging factors, innate immune cells, costimulatory pathways, immune cell signalling, immuno-regulatory cell types, biomarkers of GVHD and regenerative approaches. New insight in the pathogenesis of acute GVHD has revealed the role of pro-inflammatory intracellular signalling, defects in intestinal tissue regeneration and anti-bacterial defence, as well as a reduced diversity of the microbiome, which will be the basis for the development of novel therapies.
引用
- Zeiser R. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol. 2019. PMID: 31588560. doi:10.1111/bjh.16190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。